ARTICLE | Deals
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
December 10, 2024 12:14 AM UTC
A licensing deal last week was the latest development for a program its sponsor has said was affected profoundly by the Inflation Reduction Act, leading to a strategic shift.
Relay Therapeutics Inc. (NASDAQ:RLAY) has out-licensed what was once its lead program, handing off the FGFR2 inhibitor to privately held Elevar Therapeutics Inc. after determining that its planned fast-to-market strategy was no longer worth pursuing…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654411/frustrated-by-ira-relay-out-licenses-nda-ready-program-to-elevar